CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection
2020 · Transplantation · 110 citations
https://doi.org/10.1097/tp.0000000000003247
G
Guido A. Gualdoni
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
1.3K
Citations
17
h-index
23
i10-index
Guido A. Gualdoni is an academic researcher from Telstra (Australia). The author has contributed to research in topics: Immune Cell Function and Interaction & Cytomegalovirus and herpesvirus research & Renal Transplantation Outcomes and Treatments. The author has an h-index of 17, co-authored 26 publications.
ORCID: 0000-0001-9490-0197Papers by this author
worksNext generation sequencing based assessment of the alloreactive T cell receptor repertoire in kidney transplant patients during rejection: a prospective cohort study
2019 · BMC Nephrology · 18 citations
https://doi.org/10.1186/s12882-019-1541-5
MxA for differentiating viral and bacterial infections in adults: a prospective, exploratory study
2023 · Infection · 13 citations
https://doi.org/10.1007/s15010-023-01986-0
Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2
2022 · Journal of Virus Eradication · 9 citations
https://doi.org/10.1016/j.jve.2022.100305
Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models
2025 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-025-94476-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat